Big picture - Why invest in Futura Medical PLC
Futura Medical PLC Snapshot
Futura Medical is developing a portfolio of products in pain relief and sexual health. Our strategy is to develop our portfolio of innovative products for two large market categories, sexual health and pain, and then partner at the optimum time to generate most value.
Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology.
Our research and development strategy
We focus exclusively on topically applied pharmaceutical drugs, ancillary medicinal substances and functional excipients for the over the counter and prescription markets. We only incorporate existing well-characterised chemical entities into our products. This strategy gives us a lower development risk profile compared with developing new chemical entities. As a result, the overall risk of the investment is reduced as our strategy increases the likelihood of regulatory approval and lowers the cost of development.
We specialise in sexual health and pain relief and have five core products in our development pipeline:
Board of Directors
Non-Executive Chairman and Chairman of Nomination Committee
Current roles: John Clarke became Chairman of Futura Medical plc in 2012. He is a member of the Nominations Committee and the Remuneration Committee. He is also the Non-Executive Chairman of Science in Sport plc and Kind Consumer Holdings Limited and a senior advisor to Helios Investment Partners LLP.
Past roles: Appointed President of GSK Consumer Healthcare in 2006, a position from which he stepped down in 2011. Under his leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. Non-executive Chairman of Quantum Pharma Plc.
Brings to the Board: Extensive experience of the healthcare sector, having worked at GSK for more than 35 years.
Current roles: James Barder joined the Group as Chief Executive in 2001. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations matters and leads commercial negotiations. He first became involved with the Group in 1997.
Past roles: Managing Director of Aon Capital Markets Limited and Non-Executive Director of Lorega Limited. James has predominantly worked in the field of insurance and finance including firms he founded.
Brings to the Board: Over 25 years of experience in setting up, managing and running companies.
Finance Director and Chief Operating Officer
Current roles: Angela joined the company in February 2018. She leads the Group's finance, HR and IT functions, inputs into commercial and financial strategy, ensures its compliance procedures and is a principal contact for shareholder and investor relations matters.
Past roles: Senior financial roles in a diverse range of industries, including the past 7 years as UK Finance Director at Shield Therapeutics Plc (listed on AIM stock exchange).
Brings to the Board: Strategic and operational financial experience of developing and commercialising pharmaceutical products.
Executive Director and Head of R&D
Current roles: Ken James joined the Board in April 2016. In November 2016 he was appointed Head of R&D. He oversees the development, regulatory and manufacturing strategies for the company's existing pipeline and the evaluation of early stage pipeline opportunities. He is a member of the Nominations Committee, the Remuneration Committee and the Audit Committee.
Past roles: Senior Vice President of Research and Development for GlaxoSmithKline Worldwide Consumer Healthcare, having worked in the UK and the United States.
Brings to the Board: Over 40 years' experience in the research, development and commercialisation of consumer healthcare products.
Jonathan Freeman, BA (Hons), MBA
Senior Independent Non-Executive Director and
Chairman of Remuneration Committee and Audit Committee
Current roles: Jonathan Freeman joined the Board in 2003 and was appointed Senior Independent Non-Executive Director in November 2003. He chairs the Audit Committee and the Remuneration Committee and is also a member of the Nominations Committee. He is also an Executive Director of Braveheart Investment Group plc, a Director of PhotonStar LED Group plc and a Non-Executive Director of European Wealth Group Limited.
Past roles: Director of Beeson Gregory, Chief Executive Officer of Syndicate Asset Management plc and a Director of Hume Securities plc.
Brings to the Board: Over 25 years of experience in the financial services sector, guidance on City regulatory matters, corporate finance and investor relations.
Share statistics (as at 19 November 2018)
|Number of Ordinary Shares in issue (undiluted)||204,583,439|
|Number of Ordinary Shares subject to options||5,950,000|
|Maximum number of Ordinary Shares in issue (fully diluted)||213,778,252|
The effect of the options, if all were exercised, would be to increase the issued share capital by 2.91% and raise £2,313,050 for the Company.
There are no restrictions on the transfer of Futura Medical plc shares.
Major shareholders (as at 19 November 2018)
Shareholders holding more than 3% of the share capital of Futura were:
|Lombard Odier Asset Management (Europe) Limited||23.99%|
|WT Lamb Investments Limited||
Futura Medical Head Office
Surrey Technology Centre
40 Occam Road
Telephone: +44 (0) 1483 685670
Fax: +44 (0) 1483 685671
Email: [email protected]
Public relations and media
Optimum Strategic Communications
8 Devonshire Square
Tel: +44 (0) 203 950 9144
Email: [email protected]
Investor Contacts and Advisors
Nominated Adviser and broker
1 Bartholomew Lane
Arlington Business Park
Link Asset Services
34 Beckenham Road
Square One Law
Anson House, Burdon Terrace
Newcastle upon Tyne
Withers and Rogers LLP
4 More London Riverside
PO Box 160
12A North Street